Market Cap 130.17B
Revenue (ttm) 28.75B
Net Income (ttm) 480.00M
EPS (ttm) N/A
PE Ratio 22.75
Forward PE 13.35
Profit Margin 1.67%
Debt to Equity Ratio 1.46
Volume 8,066,700
Avg Vol 9,843,380
Day's Range N/A - N/A
Shares Out 1.25B
Stochastic %K 62%
Beta 0.32
Analysts Strong Sell
Price Target $112.24

Latest News on GILD

5 Big Biopharmaceutical Stocks That Are Finding Favor

Mar 5, 2025, 1:31 PM EST - 6 weeks ago

5 Big Biopharmaceutical Stocks That Are Finding Favor

ABBV AMGN JNJ LLY


Why Gilead Sciences Remains A Buy After A 40% Rally

Feb 26, 2025, 10:55 PM EST - 7 weeks ago

Why Gilead Sciences Remains A Buy After A 40% Rally


Gilead Sciences to Present at Upcoming Investor Conferences

Feb 19, 2025, 4:05 PM EST - 2 months ago

Gilead Sciences to Present at Upcoming Investor Conferences


Calls of the Day: Gilead Sciences and Merck

Feb 18, 2025, 12:59 PM EST - 2 months ago

Calls of the Day: Gilead Sciences and Merck

MRK


Josh Brown's best stocks

Feb 14, 2025, 1:31 PM EST - 2 months ago

Josh Brown's best stocks

CTVA UNP


Gilead Sciences: Strong Q4 Results And Huge Progress In HIV

Feb 12, 2025, 8:25 AM EST - 2 months ago

Gilead Sciences: Strong Q4 Results And Huge Progress In HIV


Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript

Feb 11, 2025, 8:40 PM EST - 2 months ago

Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript


Gilead quarterly results beat estimates

Feb 11, 2025, 4:08 PM EST - 2 months ago

Gilead quarterly results beat estimates


Final Trade: UBER, MP, MGNI, GILD

Feb 5, 2025, 6:32 PM EST - 2 months ago

Final Trade: UBER, MP, MGNI, GILD

UBER MGNI MP


Gilead: Strong Sales Growth Remains With Veklury And Beyond

Feb 3, 2025, 4:56 PM EST - 2 months ago

Gilead: Strong Sales Growth Remains With Veklury And Beyond


Final Trade: ANF, GILD

Jan 13, 2025, 6:32 PM EST - 3 months ago

Final Trade: ANF, GILD

ANF


Gilead CEO on funding for new HIV prevention medicine

Jan 13, 2025, 11:15 AM EST - 3 months ago

Gilead CEO on funding for new HIV prevention medicine